Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines Inc - Ordinary Shares

In a report released on April 24, Joseph Catanzaro from Mizuho Securities maintained a Buy rating on Revolution Medicines, with a price target of $...

Mizuho Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)

Stifel Nicolaus analyst Laura Prendergast maintained a Buy rating on Revolution Medicines today and set a price target of $215.00. Prendergast cove...

Stifel Nicolaus Remains a Buy on Revolution Medicines (RVMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and Revolution Medicines (...

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Revolution Medicines (RVMD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX), Spyre Therapeutic...

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phreesia (PHR) and Revolution Medicines (RVMD). Ph...

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR) and Revolution Medicines (RVMD)

An update from Revolution Medicines ( ($RVMD) ) is now available. On April 17, 2026, Revolution Medicines issued $500 million of 0.50% Convertible ...

Revolution Medicines Raises $500 Million via Convertible Notes

Revolution Medicines ( ($RVMD) ) has issued an announcement. On April 14, 2026, Revolution Medicines, Inc. entered into an underwriting agreement w...

Revolution Medicines Raises Capital via Equity and Convertible Notes

As the market witnesses a relief rally this April, investors are turning toward stocks with strong momentum and analyst backing. For those looking ...

3 Best Trending Stocks, According to Analysts – 4/16/2026

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocular Therapeutix (OCUL) and Revolution Medicines (...

Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), Revolution Medicines (RVMD)

Traders seeking the latest stock market stories will find them in our daily roundup.


Morning News Wrap-Up 4/13/26: Today’s Biggest Stock Market Stories!

Revolution Medicines ( ($RVMD) ) just unveiled an announcement. On April 13, 2026, Revolution Medicines reported topline data from its global Phase...

Revolution Medicines Reports Positive Phase 3 Daraxonrasib Results

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $144.00. Accor...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RVMD	$131.67	-2.68%	4.77M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RVMD	$131.67	-2.7%	4.77M
3
4
5
6

RVMD

RVMD

Compare Stocks

Start Your Comparison

Get Revolution Medicines Inc - Ordinary Shares Data in Excel

Get Revolution Medicines Inc - Ordinary Shares Data in Excel